nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—lung cancer	0.472	1	CbGaD
Arformoterol—CYP2C19—Gefitinib—lung cancer	0.0398	0.147	CbGbCtD
Arformoterol—CYP2C19—Teniposide—lung cancer	0.0386	0.143	CbGbCtD
Arformoterol—CYP2C9—Gefitinib—lung cancer	0.0331	0.122	CbGbCtD
Arformoterol—CYP2C9—Teniposide—lung cancer	0.0321	0.119	CbGbCtD
Arformoterol—CYP2D6—Gefitinib—lung cancer	0.0303	0.112	CbGbCtD
Arformoterol—CYP2D6—Vinorelbine—lung cancer	0.0233	0.0862	CbGbCtD
Arformoterol—CYP2C9—Paclitaxel—lung cancer	0.0179	0.0662	CbGbCtD
Arformoterol—CYP2D6—Erlotinib—lung cancer	0.0179	0.0661	CbGbCtD
Arformoterol—CYP2C9—Cisplatin—lung cancer	0.0144	0.0532	CbGbCtD
Arformoterol—CYP2D6—Vinblastine—lung cancer	0.0144	0.0531	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—lung cancer	0.00883	0.0326	CbGbCtD
Arformoterol—Formoterol—CYP2A6—lung cancer	0.000723	0.726	CrCbGaD
Arformoterol—Isoprenaline—CYP1A1—lung cancer	0.000272	0.274	CrCbGaD
Arformoterol—Feeling abnormal—Gemcitabine—lung cancer	0.000108	0.000587	CcSEcCtD
Arformoterol—Dizziness—Vinorelbine—lung cancer	0.000108	0.000586	CcSEcCtD
Arformoterol—Nervous system disorder—Paclitaxel—lung cancer	0.000107	0.000585	CcSEcCtD
Arformoterol—Hypokalaemia—Doxorubicin—lung cancer	0.000107	0.000584	CcSEcCtD
Arformoterol—Tachycardia—Paclitaxel—lung cancer	0.000107	0.000582	CcSEcCtD
Arformoterol—Skin disorder—Paclitaxel—lung cancer	0.000106	0.000579	CcSEcCtD
Arformoterol—Abdominal pain—Irinotecan—lung cancer	0.000106	0.000578	CcSEcCtD
Arformoterol—Body temperature increased—Irinotecan—lung cancer	0.000106	0.000578	CcSEcCtD
Arformoterol—Nasopharyngitis—Doxorubicin—lung cancer	0.000105	0.000574	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Cisplatin—lung cancer	0.000105	0.000573	CcSEcCtD
Arformoterol—Hypotension—Etoposide—lung cancer	0.000104	0.000568	CcSEcCtD
Arformoterol—Gastritis—Doxorubicin—lung cancer	0.000104	0.000568	CcSEcCtD
Arformoterol—Pain—Cisplatin—lung cancer	0.000104	0.000568	CcSEcCtD
Arformoterol—Vomiting—Vinorelbine—lung cancer	0.000104	0.000564	CcSEcCtD
Arformoterol—Body temperature increased—Gemcitabine—lung cancer	0.000103	0.000563	CcSEcCtD
Arformoterol—Rash—Vinorelbine—lung cancer	0.000103	0.000559	CcSEcCtD
Arformoterol—Dermatitis—Vinorelbine—lung cancer	0.000103	0.000558	CcSEcCtD
Arformoterol—Hypotension—Paclitaxel—lung cancer	0.000102	0.000557	CcSEcCtD
Arformoterol—Headache—Vinorelbine—lung cancer	0.000102	0.000555	CcSEcCtD
Arformoterol—Conjunctivitis—Methotrexate—lung cancer	0.000102	0.000555	CcSEcCtD
Arformoterol—Influenza—Doxorubicin—lung cancer	0.000102	0.000555	CcSEcCtD
Arformoterol—Asthma—Doxorubicin—lung cancer	0.000102	0.000555	CcSEcCtD
Arformoterol—Palpitations—Docetaxel—lung cancer	0.000101	0.000547	CcSEcCtD
Arformoterol—Feeling abnormal—Cisplatin—lung cancer	0.000101	0.000547	CcSEcCtD
Arformoterol—Haematuria—Methotrexate—lung cancer	0.0001	0.000545	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Paclitaxel—lung cancer	9.98e-05	0.000543	CcSEcCtD
Arformoterol—Dyspnoea—Etoposide—lung cancer	9.96e-05	0.000542	CcSEcCtD
Arformoterol—Somnolence—Etoposide—lung cancer	9.94e-05	0.000541	CcSEcCtD
Arformoterol—Cough—Docetaxel—lung cancer	9.93e-05	0.00054	CcSEcCtD
Arformoterol—Angina pectoris—Doxorubicin—lung cancer	9.93e-05	0.00054	CcSEcCtD
Arformoterol—Insomnia—Paclitaxel—lung cancer	9.91e-05	0.000539	CcSEcCtD
Arformoterol—Hypersensitivity—Irinotecan—lung cancer	9.9e-05	0.000539	CcSEcCtD
Arformoterol—Hypertension—Docetaxel—lung cancer	9.83e-05	0.000535	CcSEcCtD
Arformoterol—Bronchitis—Doxorubicin—lung cancer	9.8e-05	0.000533	CcSEcCtD
Arformoterol—Dyspnoea—Paclitaxel—lung cancer	9.77e-05	0.000532	CcSEcCtD
Arformoterol—Somnolence—Paclitaxel—lung cancer	9.74e-05	0.00053	CcSEcCtD
Arformoterol—Myalgia—Docetaxel—lung cancer	9.69e-05	0.000527	CcSEcCtD
Arformoterol—Arthralgia—Docetaxel—lung cancer	9.69e-05	0.000527	CcSEcCtD
Arformoterol—Chest pain—Docetaxel—lung cancer	9.69e-05	0.000527	CcSEcCtD
Arformoterol—Nausea—Vinorelbine—lung cancer	9.68e-05	0.000527	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Etoposide—lung cancer	9.65e-05	0.000525	CcSEcCtD
Arformoterol—Dyspepsia—Paclitaxel—lung cancer	9.65e-05	0.000525	CcSEcCtD
Arformoterol—Body temperature increased—Cisplatin—lung cancer	9.64e-05	0.000525	CcSEcCtD
Arformoterol—Asthenia—Irinotecan—lung cancer	9.64e-05	0.000525	CcSEcCtD
Arformoterol—Fatigue—Etoposide—lung cancer	9.64e-05	0.000524	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	9.62e-05	0.000524	CcSEcCtD
Arformoterol—Constipation—Etoposide—lung cancer	9.56e-05	0.00052	CcSEcCtD
Arformoterol—Pain—Etoposide—lung cancer	9.56e-05	0.00052	CcSEcCtD
Arformoterol—Dry mouth—Docetaxel—lung cancer	9.48e-05	0.000516	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Doxorubicin—lung cancer	9.47e-05	0.000516	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Paclitaxel—lung cancer	9.46e-05	0.000515	CcSEcCtD
Arformoterol—Fatigue—Paclitaxel—lung cancer	9.45e-05	0.000514	CcSEcCtD
Arformoterol—Asthenia—Gemcitabine—lung cancer	9.39e-05	0.000511	CcSEcCtD
Arformoterol—Constipation—Paclitaxel—lung cancer	9.37e-05	0.00051	CcSEcCtD
Arformoterol—Pain—Paclitaxel—lung cancer	9.37e-05	0.00051	CcSEcCtD
Arformoterol—Pharyngitis—Methotrexate—lung cancer	9.35e-05	0.000509	CcSEcCtD
Arformoterol—Urinary tract disorder—Methotrexate—lung cancer	9.31e-05	0.000506	CcSEcCtD
Arformoterol—Anaphylactic shock—Docetaxel—lung cancer	9.29e-05	0.000505	CcSEcCtD
Arformoterol—Oedema—Docetaxel—lung cancer	9.29e-05	0.000505	CcSEcCtD
Arformoterol—Pruritus—Gemcitabine—lung cancer	9.26e-05	0.000504	CcSEcCtD
Arformoterol—Urethral disorder—Methotrexate—lung cancer	9.24e-05	0.000503	CcSEcCtD
Arformoterol—Infection—Docetaxel—lung cancer	9.23e-05	0.000502	CcSEcCtD
Arformoterol—Feeling abnormal—Etoposide—lung cancer	9.21e-05	0.000501	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—lung cancer	9.2e-05	0.0005	CcSEcCtD
Arformoterol—Diarrhoea—Irinotecan—lung cancer	9.19e-05	0.0005	CcSEcCtD
Arformoterol—Gastrointestinal pain—Etoposide—lung cancer	9.14e-05	0.000497	CcSEcCtD
Arformoterol—Nervous system disorder—Docetaxel—lung cancer	9.11e-05	0.000496	CcSEcCtD
Arformoterol—Visual impairment—Methotrexate—lung cancer	9.08e-05	0.000494	CcSEcCtD
Arformoterol—Tachycardia—Docetaxel—lung cancer	9.07e-05	0.000493	CcSEcCtD
Arformoterol—Feeling abnormal—Paclitaxel—lung cancer	9.03e-05	0.000491	CcSEcCtD
Arformoterol—Skin disorder—Docetaxel—lung cancer	9.02e-05	0.000491	CcSEcCtD
Arformoterol—Hypersensitivity—Cisplatin—lung cancer	8.99e-05	0.000489	CcSEcCtD
Arformoterol—Gastrointestinal pain—Paclitaxel—lung cancer	8.96e-05	0.000488	CcSEcCtD
Arformoterol—Diarrhoea—Gemcitabine—lung cancer	8.96e-05	0.000487	CcSEcCtD
Arformoterol—Dizziness—Irinotecan—lung cancer	8.89e-05	0.000484	CcSEcCtD
Arformoterol—Urticaria—Etoposide—lung cancer	8.88e-05	0.000483	CcSEcCtD
Arformoterol—Abdominal pain—Etoposide—lung cancer	8.84e-05	0.000481	CcSEcCtD
Arformoterol—Body temperature increased—Etoposide—lung cancer	8.84e-05	0.000481	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—lung cancer	8.84e-05	0.000481	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—lung cancer	8.84e-05	0.000481	CcSEcCtD
Arformoterol—Asthenia—Cisplatin—lung cancer	8.75e-05	0.000476	CcSEcCtD
Arformoterol—Cardiac disorder—Methotrexate—lung cancer	8.75e-05	0.000476	CcSEcCtD
Arformoterol—Urticaria—Paclitaxel—lung cancer	8.71e-05	0.000474	CcSEcCtD
Arformoterol—Hypotension—Docetaxel—lung cancer	8.68e-05	0.000472	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—lung cancer	8.67e-05	0.000472	CcSEcCtD
Arformoterol—Abdominal pain—Paclitaxel—lung cancer	8.66e-05	0.000471	CcSEcCtD
Arformoterol—Body temperature increased—Paclitaxel—lung cancer	8.66e-05	0.000471	CcSEcCtD
Arformoterol—Vomiting—Irinotecan—lung cancer	8.54e-05	0.000465	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—lung cancer	8.53e-05	0.000464	CcSEcCtD
Arformoterol—Immune system disorder—Methotrexate—lung cancer	8.51e-05	0.000463	CcSEcCtD
Arformoterol—Mediastinal disorder—Methotrexate—lung cancer	8.49e-05	0.000462	CcSEcCtD
Arformoterol—Rash—Irinotecan—lung cancer	8.47e-05	0.000461	CcSEcCtD
Arformoterol—Dermatitis—Irinotecan—lung cancer	8.46e-05	0.000461	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Docetaxel—lung cancer	8.46e-05	0.000461	CcSEcCtD
Arformoterol—Headache—Irinotecan—lung cancer	8.42e-05	0.000458	CcSEcCtD
Arformoterol—Insomnia—Docetaxel—lung cancer	8.4e-05	0.000457	CcSEcCtD
Arformoterol—Diarrhoea—Cisplatin—lung cancer	8.35e-05	0.000454	CcSEcCtD
Arformoterol—Vomiting—Gemcitabine—lung cancer	8.32e-05	0.000453	CcSEcCtD
Arformoterol—Dyspnoea—Docetaxel—lung cancer	8.28e-05	0.000451	CcSEcCtD
Arformoterol—Somnolence—Docetaxel—lung cancer	8.26e-05	0.000449	CcSEcCtD
Arformoterol—Mental disorder—Methotrexate—lung cancer	8.26e-05	0.000449	CcSEcCtD
Arformoterol—Rash—Gemcitabine—lung cancer	8.25e-05	0.000449	CcSEcCtD
Arformoterol—Dermatitis—Gemcitabine—lung cancer	8.25e-05	0.000449	CcSEcCtD
Arformoterol—Hypersensitivity—Etoposide—lung cancer	8.23e-05	0.000448	CcSEcCtD
Arformoterol—Malnutrition—Methotrexate—lung cancer	8.2e-05	0.000446	CcSEcCtD
Arformoterol—Headache—Gemcitabine—lung cancer	8.2e-05	0.000446	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—lung cancer	8.18e-05	0.000445	CcSEcCtD
Arformoterol—Dyspepsia—Docetaxel—lung cancer	8.18e-05	0.000445	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—lung cancer	8.1e-05	0.000441	CcSEcCtD
Arformoterol—Hypersensitivity—Paclitaxel—lung cancer	8.07e-05	0.000439	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—lung cancer	8.06e-05	0.000438	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—lung cancer	8.04e-05	0.000437	CcSEcCtD
Arformoterol—Dysgeusia—Methotrexate—lung cancer	8.03e-05	0.000437	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Docetaxel—lung cancer	8.02e-05	0.000436	CcSEcCtD
Arformoterol—Asthenia—Etoposide—lung cancer	8.02e-05	0.000436	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—lung cancer	8.02e-05	0.000436	CcSEcCtD
Arformoterol—Fatigue—Docetaxel—lung cancer	8.01e-05	0.000436	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—lung cancer	8e-05	0.000435	CcSEcCtD
Arformoterol—Nausea—Irinotecan—lung cancer	7.98e-05	0.000434	CcSEcCtD
Arformoterol—Pain—Docetaxel—lung cancer	7.94e-05	0.000432	CcSEcCtD
Arformoterol—Constipation—Docetaxel—lung cancer	7.94e-05	0.000432	CcSEcCtD
Arformoterol—Back pain—Methotrexate—lung cancer	7.93e-05	0.000432	CcSEcCtD
Arformoterol—Pruritus—Etoposide—lung cancer	7.91e-05	0.00043	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—lung cancer	7.86e-05	0.000428	CcSEcCtD
Arformoterol—Asthenia—Paclitaxel—lung cancer	7.86e-05	0.000428	CcSEcCtD
Arformoterol—Nausea—Gemcitabine—lung cancer	7.77e-05	0.000423	CcSEcCtD
Arformoterol—Vomiting—Cisplatin—lung cancer	7.76e-05	0.000422	CcSEcCtD
Arformoterol—Pruritus—Paclitaxel—lung cancer	7.75e-05	0.000422	CcSEcCtD
Arformoterol—Rash—Cisplatin—lung cancer	7.69e-05	0.000419	CcSEcCtD
Arformoterol—Dermatitis—Cisplatin—lung cancer	7.69e-05	0.000418	CcSEcCtD
Arformoterol—Feeling abnormal—Docetaxel—lung cancer	7.65e-05	0.000417	CcSEcCtD
Arformoterol—Diarrhoea—Etoposide—lung cancer	7.65e-05	0.000416	CcSEcCtD
Arformoterol—Ill-defined disorder—Methotrexate—lung cancer	7.61e-05	0.000414	CcSEcCtD
Arformoterol—Gastrointestinal pain—Docetaxel—lung cancer	7.6e-05	0.000413	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—lung cancer	7.57e-05	0.000412	CcSEcCtD
Arformoterol—Diarrhoea—Paclitaxel—lung cancer	7.5e-05	0.000408	CcSEcCtD
Arformoterol—Malaise—Methotrexate—lung cancer	7.4e-05	0.000403	CcSEcCtD
Arformoterol—Dizziness—Etoposide—lung cancer	7.39e-05	0.000402	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—lung cancer	7.37e-05	0.000401	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—lung cancer	7.35e-05	0.0004	CcSEcCtD
Arformoterol—Body temperature increased—Docetaxel—lung cancer	7.34e-05	0.0004	CcSEcCtD
Arformoterol—Abdominal pain—Docetaxel—lung cancer	7.34e-05	0.0004	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—lung cancer	7.29e-05	0.000397	CcSEcCtD
Arformoterol—Dizziness—Paclitaxel—lung cancer	7.25e-05	0.000394	CcSEcCtD
Arformoterol—Nausea—Cisplatin—lung cancer	7.25e-05	0.000394	CcSEcCtD
Arformoterol—Cough—Methotrexate—lung cancer	7.16e-05	0.00039	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—lung cancer	7.15e-05	0.000389	CcSEcCtD
Arformoterol—Vomiting—Etoposide—lung cancer	7.11e-05	0.000387	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—lung cancer	7.1e-05	0.000387	CcSEcCtD
Arformoterol—Rash—Etoposide—lung cancer	7.05e-05	0.000383	CcSEcCtD
Arformoterol—Dermatitis—Etoposide—lung cancer	7.04e-05	0.000383	CcSEcCtD
Arformoterol—Headache—Etoposide—lung cancer	7e-05	0.000381	CcSEcCtD
Arformoterol—Arthralgia—Methotrexate—lung cancer	6.98e-05	0.00038	CcSEcCtD
Arformoterol—Chest pain—Methotrexate—lung cancer	6.98e-05	0.00038	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—lung cancer	6.98e-05	0.00038	CcSEcCtD
Arformoterol—Tension—Doxorubicin—lung cancer	6.97e-05	0.000379	CcSEcCtD
Arformoterol—Vomiting—Paclitaxel—lung cancer	6.97e-05	0.000379	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—lung cancer	6.96e-05	0.000379	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	6.94e-05	0.000377	CcSEcCtD
Arformoterol—Rash—Paclitaxel—lung cancer	6.91e-05	0.000376	CcSEcCtD
Arformoterol—Dermatitis—Paclitaxel—lung cancer	6.9e-05	0.000376	CcSEcCtD
Arformoterol—Discomfort—Methotrexate—lung cancer	6.9e-05	0.000375	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—lung cancer	6.9e-05	0.000375	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—lung cancer	6.87e-05	0.000374	CcSEcCtD
Arformoterol—Headache—Paclitaxel—lung cancer	6.87e-05	0.000374	CcSEcCtD
Arformoterol—Hypersensitivity—Docetaxel—lung cancer	6.84e-05	0.000372	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—lung cancer	6.83e-05	0.000372	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—lung cancer	6.69e-05	0.000364	CcSEcCtD
Arformoterol—Asthenia—Docetaxel—lung cancer	6.66e-05	0.000363	CcSEcCtD
Arformoterol—Infection—Methotrexate—lung cancer	6.65e-05	0.000362	CcSEcCtD
Arformoterol—Nausea—Etoposide—lung cancer	6.64e-05	0.000361	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—lung cancer	6.59e-05	0.000359	CcSEcCtD
Arformoterol—Pruritus—Docetaxel—lung cancer	6.57e-05	0.000358	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—lung cancer	6.57e-05	0.000357	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—lung cancer	6.53e-05	0.000355	CcSEcCtD
Arformoterol—Nausea—Paclitaxel—lung cancer	6.51e-05	0.000354	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—lung cancer	6.5e-05	0.000354	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—lung cancer	6.41e-05	0.000349	CcSEcCtD
Arformoterol—Diarrhoea—Docetaxel—lung cancer	6.36e-05	0.000346	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—lung cancer	6.28e-05	0.000342	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—lung cancer	6.26e-05	0.00034	CcSEcCtD
Arformoterol—Cough—Doxorubicin—lung cancer	6.2e-05	0.000337	CcSEcCtD
Arformoterol—Dizziness—Docetaxel—lung cancer	6.14e-05	0.000334	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—lung cancer	6.13e-05	0.000334	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—lung cancer	6.1e-05	0.000332	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—lung cancer	6.06e-05	0.00033	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—lung cancer	6.05e-05	0.000329	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—lung cancer	6.05e-05	0.000329	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—lung cancer	6.05e-05	0.000329	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—lung cancer	6.03e-05	0.000328	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.01e-05	0.000327	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—lung cancer	5.97e-05	0.000325	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—lung cancer	5.97e-05	0.000325	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—lung cancer	5.95e-05	0.000324	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—lung cancer	5.91e-05	0.000322	CcSEcCtD
Arformoterol—Vomiting—Docetaxel—lung cancer	5.91e-05	0.000321	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—lung cancer	5.89e-05	0.000321	CcSEcCtD
Arformoterol—Rash—Docetaxel—lung cancer	5.86e-05	0.000319	CcSEcCtD
Arformoterol—Dermatitis—Docetaxel—lung cancer	5.85e-05	0.000318	CcSEcCtD
Arformoterol—Headache—Docetaxel—lung cancer	5.82e-05	0.000317	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—lung cancer	5.8e-05	0.000315	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—lung cancer	5.8e-05	0.000315	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—lung cancer	5.78e-05	0.000315	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—lung cancer	5.77e-05	0.000314	CcSEcCtD
Arformoterol—Infection—Doxorubicin—lung cancer	5.76e-05	0.000313	CcSEcCtD
Arformoterol—Pain—Methotrexate—lung cancer	5.73e-05	0.000312	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—lung cancer	5.69e-05	0.000309	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—lung cancer	5.66e-05	0.000308	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—lung cancer	5.63e-05	0.000306	CcSEcCtD
Arformoterol—Nausea—Docetaxel—lung cancer	5.52e-05	0.0003	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—lung cancer	5.52e-05	0.0003	CcSEcCtD
Arformoterol—Gastrointestinal pain—Methotrexate—lung cancer	5.47e-05	0.000298	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—lung cancer	5.42e-05	0.000295	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—lung cancer	5.32e-05	0.000289	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—lung cancer	5.29e-05	0.000288	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—lung cancer	5.29e-05	0.000288	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.28e-05	0.000287	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—lung cancer	5.24e-05	0.000285	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—lung cancer	5.17e-05	0.000281	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—lung cancer	5.15e-05	0.00028	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—lung cancer	5.1e-05	0.000278	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—lung cancer	5e-05	0.000272	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—lung cancer	5e-05	0.000272	CcSEcCtD
Arformoterol—Pain—Doxorubicin—lung cancer	4.96e-05	0.00027	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—lung cancer	4.96e-05	0.00027	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—lung cancer	4.93e-05	0.000268	CcSEcCtD
Arformoterol—Asthenia—Methotrexate—lung cancer	4.8e-05	0.000261	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—lung cancer	4.78e-05	0.00026	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—lung cancer	4.74e-05	0.000258	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—lung cancer	4.74e-05	0.000258	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—lung cancer	4.61e-05	0.000251	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—lung cancer	4.58e-05	0.000249	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—lung cancer	4.58e-05	0.000249	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—lung cancer	4.58e-05	0.000249	CcSEcCtD
Arformoterol—Dizziness—Methotrexate—lung cancer	4.43e-05	0.000241	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—lung cancer	4.27e-05	0.000232	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—lung cancer	4.26e-05	0.000232	CcSEcCtD
Arformoterol—Rash—Methotrexate—lung cancer	4.22e-05	0.00023	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—lung cancer	4.22e-05	0.000229	CcSEcCtD
Arformoterol—Headache—Methotrexate—lung cancer	4.19e-05	0.000228	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—lung cancer	4.16e-05	0.000226	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—lung cancer	4.1e-05	0.000223	CcSEcCtD
Arformoterol—Nausea—Methotrexate—lung cancer	3.98e-05	0.000216	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—lung cancer	3.97e-05	0.000216	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—lung cancer	3.83e-05	0.000209	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—lung cancer	3.69e-05	0.000201	CcSEcCtD
Arformoterol—Rash—Doxorubicin—lung cancer	3.66e-05	0.000199	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—lung cancer	3.65e-05	0.000199	CcSEcCtD
Arformoterol—Headache—Doxorubicin—lung cancer	3.63e-05	0.000198	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—lung cancer	3.44e-05	0.000187	CcSEcCtD
Arformoterol—CYP2C19—Metabolism—HPGDS—lung cancer	1.2e-05	0.000165	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ENO2—lung cancer	1.2e-05	0.000165	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPP2R1B—lung cancer	1.19e-05	0.000164	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALDOA—lung cancer	1.19e-05	0.000164	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1R—lung cancer	1.19e-05	0.000164	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCL8—lung cancer	1.18e-05	0.000163	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALDOA—lung cancer	1.18e-05	0.000163	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.17e-05	0.000162	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HES1—lung cancer	1.17e-05	0.000161	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1R—lung cancer	1.16e-05	0.00016	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTT1—lung cancer	1.16e-05	0.00016	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCL8—lung cancer	1.16e-05	0.00016	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA3—lung cancer	1.15e-05	0.000159	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—lung cancer	1.15e-05	0.000159	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GCLC—lung cancer	1.15e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2A6—lung cancer	1.15e-05	0.000158	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—RAF1—lung cancer	1.14e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA3—lung cancer	1.14e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.14e-05	0.000158	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HES1—lung cancer	1.14e-05	0.000158	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ERCC2—lung cancer	1.14e-05	0.000157	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—lung cancer	1.13e-05	0.000156	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.12e-05	0.000155	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCG2—lung cancer	1.12e-05	0.000155	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ADCY1—lung cancer	1.12e-05	0.000155	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—RAF1—lung cancer	1.12e-05	0.000155	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CB—lung cancer	1.12e-05	0.000154	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ADCY1—lung cancer	1.11e-05	0.000154	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCG2—lung cancer	1.11e-05	0.000154	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—lung cancer	1.1e-05	0.000153	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HPGDS—lung cancer	1.1e-05	0.000152	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO2—lung cancer	1.1e-05	0.000152	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPP2R1B—lung cancer	1.09e-05	0.000151	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CB—lung cancer	1.09e-05	0.000151	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HPGDS—lung cancer	1.09e-05	0.000151	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO2—lung cancer	1.09e-05	0.000151	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ENO1—lung cancer	1.09e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPP2R1B—lung cancer	1.08e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.08e-05	0.00015	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—lung cancer	1.07e-05	0.000148	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.07e-05	0.000148	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.07e-05	0.000148	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—lung cancer	1.07e-05	0.000147	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB3—lung cancer	1.07e-05	0.000147	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—lung cancer	1.06e-05	0.000146	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2A6—lung cancer	1.05e-05	0.000146	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GCLC—lung cancer	1.05e-05	0.000146	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—lung cancer	1.05e-05	0.000145	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GCLC—lung cancer	1.04e-05	0.000144	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2A6—lung cancer	1.04e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB3—lung cancer	1.04e-05	0.000144	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.04e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—lung cancer	1.03e-05	0.000142	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—lung cancer	1.02e-05	0.000141	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—lung cancer	1e-05	0.000139	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—lung cancer	9.99e-06	0.000138	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO1—lung cancer	9.99e-06	0.000138	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGFR1—lung cancer	9.92e-06	0.000137	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO1—lung cancer	9.9e-06	0.000137	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	9.87e-06	0.000136	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—APOA1—lung cancer	9.85e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HIF1A—lung cancer	9.77e-06	0.000135	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2E1—lung cancer	9.74e-06	0.000135	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	9.74e-06	0.000135	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGFR1—lung cancer	9.7e-06	0.000134	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NQO1—lung cancer	9.63e-06	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HIF1A—lung cancer	9.56e-06	0.000132	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	9.43e-06	0.00013	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APOA1—lung cancer	9.43e-06	0.00013	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	9.35e-06	0.000129	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—lung cancer	9.34e-06	0.000129	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APOA1—lung cancer	9.22e-06	0.000127	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—lung cancer	9.14e-06	0.000126	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—lung cancer	8.99e-06	0.000124	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2E1—lung cancer	8.96e-06	0.000124	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2E1—lung cancer	8.88e-06	0.000123	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NQO1—lung cancer	8.86e-06	0.000122	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NQO1—lung cancer	8.78e-06	0.000121	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—STK11—lung cancer	8.68e-06	0.00012	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—lung cancer	8.61e-06	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—lung cancer	8.61e-06	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—lung cancer	8.61e-06	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—NRAS—lung cancer	8.61e-06	0.000119	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	8.6e-06	0.000119	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—POMC—lung cancer	8.56e-06	0.000118	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	8.52e-06	0.000118	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGF—lung cancer	8.51e-06	0.000118	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—lung cancer	8.42e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—lung cancer	8.42e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—lung cancer	8.42e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—NRAS—lung cancer	8.42e-06	0.000116	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CREBBP—lung cancer	8.34e-06	0.000115	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGF—lung cancer	8.32e-06	0.000115	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—lung cancer	8.24e-06	0.000114	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—POMC—lung cancer	8.19e-06	0.000113	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	8.15e-06	0.000113	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—lung cancer	8.09e-06	0.000112	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—lung cancer	8.06e-06	0.000111	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—lung cancer	8.03e-06	0.000111	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—POMC—lung cancer	8.01e-06	0.000111	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6R—lung cancer	7.99e-06	0.00011	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—STK11—lung cancer	7.99e-06	0.00011	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CREBBP—lung cancer	7.98e-06	0.00011	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—STK11—lung cancer	7.92e-06	0.000109	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—lung cancer	7.91e-06	0.000109	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—lung cancer	7.9e-06	0.000109	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—lung cancer	7.84e-06	0.000108	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CAT—lung cancer	7.82e-06	0.000108	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6R—lung cancer	7.82e-06	0.000108	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CREBBP—lung cancer	7.81e-06	0.000108	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—lung cancer	7.8e-06	0.000108	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.77e-06	0.000107	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—lung cancer	7.67e-06	0.000106	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAP2K1—lung cancer	7.62e-06	0.000105	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—lung cancer	7.61e-06	0.000105	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—lung cancer	7.57e-06	0.000105	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	7.49e-06	0.000104	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMS—lung cancer	7.47e-06	0.000103	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAP2K1—lung cancer	7.45e-06	0.000103	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	7.43e-06	0.000103	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—lung cancer	7.41e-06	0.000102	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—lung cancer	7.4e-06	0.000102	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—lung cancer	7.39e-06	0.000102	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—lung cancer	7.38e-06	0.000102	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	7.33e-06	0.000101	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—lung cancer	7.33e-06	0.000101	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—lung cancer	7.25e-06	0.0001	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CAT—lung cancer	7.19e-06	9.94e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CAT—lung cancer	7.13e-06	9.85e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.09e-06	9.8e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—lung cancer	7e-06	9.67e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—lung cancer	7e-06	9.67e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ERCC2—lung cancer	6.94e-06	9.59e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—lung cancer	6.93e-06	9.58e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—lung cancer	6.89e-06	9.52e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMS—lung cancer	6.87e-06	9.49e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—lung cancer	6.83e-06	9.43e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMS—lung cancer	6.81e-06	9.41e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	6.81e-06	9.41e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—lung cancer	6.79e-06	9.39e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—lung cancer	6.78e-06	9.37e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAF1—lung cancer	6.76e-06	9.34e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—lung cancer	6.73e-06	9.3e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—lung cancer	6.68e-06	9.24e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	6.66e-06	9.2e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—lung cancer	6.63e-06	9.16e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RAF1—lung cancer	6.61e-06	9.13e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—lung cancer	6.6e-06	9.11e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—lung cancer	6.6e-06	9.11e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—lung cancer	6.54e-06	9.03e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—lung cancer	6.45e-06	8.92e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—lung cancer	6.45e-06	8.92e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—lung cancer	6.44e-06	8.9e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ERCC2—lung cancer	6.38e-06	8.82e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—lung cancer	6.38e-06	8.82e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—lung cancer	6.34e-06	8.76e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ERCC2—lung cancer	6.33e-06	8.75e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—lung cancer	6.3e-06	8.7e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—lung cancer	6.2e-06	8.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—lung cancer	6.16e-06	8.51e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—lung cancer	6.12e-06	8.46e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—lung cancer	6.07e-06	8.38e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—lung cancer	6.06e-06	8.37e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—lung cancer	6.03e-06	8.33e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—APOA1—lung cancer	6.01e-06	8.3e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—lung cancer	5.99e-06	8.28e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—lung cancer	5.95e-06	8.23e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—lung cancer	5.93e-06	8.2e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—lung cancer	5.92e-06	8.19e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—lung cancer	5.9e-06	8.16e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—lung cancer	5.9e-06	8.15e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—lung cancer	5.89e-06	8.14e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—lung cancer	5.78e-06	7.98e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—lung cancer	5.76e-06	7.97e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.75e-06	7.95e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—lung cancer	5.73e-06	7.92e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—lung cancer	5.71e-06	7.89e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—lung cancer	5.7e-06	7.88e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—EP300—lung cancer	5.68e-06	7.85e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—lung cancer	5.61e-06	7.75e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—lung cancer	5.59e-06	7.72e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—lung cancer	5.57e-06	7.7e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—lung cancer	5.56e-06	7.68e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—APOA1—lung cancer	5.52e-06	7.63e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—lung cancer	5.48e-06	7.58e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—APOA1—lung cancer	5.48e-06	7.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—lung cancer	5.44e-06	7.52e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EP300—lung cancer	5.43e-06	7.51e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EP300—lung cancer	5.32e-06	7.35e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—lung cancer	5.29e-06	7.3e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.24e-06	7.25e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—POMC—lung cancer	5.22e-06	7.21e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—lung cancer	5.17e-06	7.14e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—lung cancer	5.15e-06	7.11e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—lung cancer	5.1e-06	7.04e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NRAS—lung cancer	5.08e-06	7.03e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CREBBP—lung cancer	5.08e-06	7.02e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—lung cancer	5.04e-06	6.97e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—lung cancer	5.04e-06	6.96e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—lung cancer	5e-06	6.91e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—lung cancer	4.99e-06	6.89e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NRAS—lung cancer	4.97e-06	6.87e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—lung cancer	4.87e-06	6.73e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—lung cancer	4.82e-06	6.66e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—POMC—lung cancer	4.8e-06	6.63e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—lung cancer	4.76e-06	6.58e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—POMC—lung cancer	4.76e-06	6.58e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—lung cancer	4.76e-06	6.58e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—lung cancer	4.74e-06	6.55e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CREBBP—lung cancer	4.68e-06	6.46e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CREBBP—lung cancer	4.63e-06	6.41e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—lung cancer	4.63e-06	6.4e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—lung cancer	4.63e-06	6.4e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—lung cancer	4.53e-06	6.26e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—lung cancer	4.43e-06	6.13e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—lung cancer	4.39e-06	6.07e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—lung cancer	4.38e-06	6.05e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—lung cancer	4.38e-06	6.05e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—lung cancer	4.34e-06	6e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—lung cancer	4.28e-06	5.92e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—lung cancer	4.2e-06	5.81e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—lung cancer	4.2e-06	5.8e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—lung cancer	4.16e-06	5.75e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—lung cancer	4.02e-06	5.56e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—lung cancer	3.93e-06	5.44e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—lung cancer	3.89e-06	5.38e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—lung cancer	3.86e-06	5.34e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—lung cancer	3.83e-06	5.29e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—lung cancer	3.83e-06	5.29e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—lung cancer	3.8e-06	5.26e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—lung cancer	3.8e-06	5.25e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—lung cancer	3.72e-06	5.14e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—lung cancer	3.64e-06	5.03e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—lung cancer	3.63e-06	5.02e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—lung cancer	3.56e-06	4.92e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—lung cancer	3.48e-06	4.81e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—EP300—lung cancer	3.46e-06	4.78e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—lung cancer	3.43e-06	4.74e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—lung cancer	3.34e-06	4.61e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—lung cancer	3.31e-06	4.57e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—lung cancer	3.28e-06	4.54e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—lung cancer	3.21e-06	4.44e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—EP300—lung cancer	3.18e-06	4.4e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—EP300—lung cancer	3.16e-06	4.36e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—lung cancer	2.56e-06	3.54e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—lung cancer	2.36e-06	3.26e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—lung cancer	2.34e-06	3.23e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—lung cancer	2.09e-06	2.89e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—lung cancer	1.92e-06	2.66e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—lung cancer	1.91e-06	2.64e-05	CbGpPWpGaD
